Genocea Biosciences (Genocea Biosciences) Days Sales Outstanding

: 0.00 (As of Mar. 2022)

View and export this data going back to 2014. Start your Free Trial

Genocea Biosciences's average Accounts Receivable for the three months ended in Mar. 2022 was $0.00 Mil. Genocea Biosciences's Revenue for the three months ended in Mar. 2022 was $0.27 Mil. Hence, Genocea Biosciences's Days Sales Outstanding for the three months ended in Mar. 2022 was 0.00.

The historical rank and industry rank for Genocea Biosciences's Days Sales Outstanding or its related term are showing as below:

GNCAQ's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.545
* Ranked among companies with meaningful Days Sales Outstanding only.

Genocea Biosciences's Days Sales Outstanding stayed the same from Mar. 2021 (0.00) to Mar. 2022 (0.00).

Genocea Biosciences Days Sales Outstanding Historical Data

The historical data trend for Genocea Biosciences's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Days Sales Outstanding

Genocea Biosciences Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Days Sales Outstanding																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Genocea Biosciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genocea Biosciences Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's Days Sales Outstanding falls into.

Genocea Biosciences Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Genocea Biosciences's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as

	Days Sales Outstanding (A: Dec. 2021 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2020 )	+	Accounts Receivable (A: Dec. 2021 ))	/	count )	/	Revenue (A: Dec. 2021 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	1.641	*	365
=	0					/	1.641	*	365
=	0.00

Genocea Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2022 is calculated as:

	Days Sales Outstanding (Q: Mar. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Mar. 2022 ))	/	count )	/	Revenue (A: Mar. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.27	*	365 / 4
=	0					/	0.27	*	365 / 4
=	0.00

Genocea Biosciences (OTCPK:GNCAQ) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Genocea Biosciences Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Genocea Biosciences (Genocea Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GNCAQ) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.genocea.com

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Executives

Jacquelyn L Sumer	officer: CHIEF LEGAL & COMPLIANCE OFF	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
William D Clark	director, officer: President and CEO	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
George Siber	director	2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023
Diantha Duvall	officer: CHIEF FINANCIAL OFFICER	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Scott D Sandell	10 percent owner
Stapleton Raymond D Jr	officer: EVP PHARM SCI & MFG	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jessica Baker Flechtner	officer: VP of Research	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815